文献速递产科母胎医学

人工胎盘生命支持系统成功治疗宫内炎症受损的极早产羊胎

Successful use of an artificial placenta-based life support system to treat extremely preterm ovine fetuses compromised by intrauterine inflammation.
PubMed 文献 · Am J Obstet Gynecol · 2020-05-04

本研究评估体外子宫环境疗法对暴露于宫内炎症的极早产羊胎(95天胎龄,约相当于人类24周)的支持能力,持续120小时。主要终点包括维持生理指标正常、无感染和炎症、无脑损伤及胎儿生长和心血管功能与宫内对照匹配。结果显示8/10胎羔完成方案,但出现难治性低血压、生长受限和 white matter injury 等挑战。

要点

  • 人工胎盘系统可支持宫内炎症暴露的极早产羊胎120小时
  • 常见并发症包括难治性低血压、生长受限和脑白质损伤
  • 临床相关模型对人工胎盘技术发展至关重要

核心结论

  • 人工胎盘系统可用于支持宫内炎症暴露的极早产羊胎,但需克服难治性低血压、生长受限和脑白质损伤等挑战。

研究设计与样本

  • 实验研究:10只单胎妊娠母羊在95天胎龄前48小时接受羊膜腔内注射10 mg大肠杆菌脂多糖,随后手术适配体外子宫环境疗法并维持120小时。
  • 对照:8只单胎妊娠母羊在93天胎龄接受同样脂多糖注射,100天胎龄处死进行对比分析。

主要发现

  • 8/10体外子宫环境组胎儿完成方案,6/8脂多糖对照组完成。
  • 体外子宫环境组6/8胎儿需地塞米松磷酸盐治疗难治性低血压。
  • 体外子宫环境组胎儿体重和冠臀长较脂多糖对照组减少(P<.05)。
  • 两组心脏超声指标、白细胞分类计数(P>.05)、血浆TNF-α和MCP-1浓度(P>.05)及肝功能无生物学显著差异。
  • 体外子宫环境组每日血培养阴性,无脑室内出血;脂多糖对照组3/6和体外子宫环境组3/8出现脑白质损伤。

临床怎么用

  • 人工胎盘技术用于极早产儿前需解决低血压、生长受限和脑白质损伤等问题,临床相关模型实验必不可少。

局限性

  • 研究为动物实验,样本量小,结果向人类临床转化需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ex vivo uterine environment therapy is an experimental intensive care strategy for extremely preterm infants born between 21 and 24 weeks of gestation. Gas exchange is performed by membranous oxygenators connected by catheters to the umbilical vessels. The fetus is submerged in a bath of synthetic amniotic fluid. The lungs remain fluid filled, and pulmonary respiration does not occur. Intrauterine inflammation is strongly associated with extremely preterm birth and fetal injury. At present, there are no data that we are aware of to show that artificial placenta-based systems can be used to support extremely preterm fetuses compromised by exposure to intrauterine inflammation. OBJECTIVE: To evaluate the ability of our ex vivo uterine environment therapy platform to support extremely preterm ovine fetuses (95-day gestational age; approximately equivalent to 24 weeks of human gestation) exposed to intrauterine inflammation for a period of 120 hours, the following primary endpoints were chosen: (1) maintenance of key physiological variables within normal ranges, (2) absence of infection and inflammation, (3) absence of brain injury, and (4) gross fetal growth and cardiovascular function matching that of age-matched in utero controls. STUDY DESIGN: Ten ewes with singleton pregnancies were each given a single intraamniotic injection of 10-mg Escherichia coli lipopolysaccharides under ultrasound guidance 48 hours before undergoing surgical delivery for adaptation to ex vivo uterine environment therapy at 95-day gestation (term=150 days). Fetuses were adapted to ex vivo uterine environment therapy and maintained for 120 hours with constant monitoring of key vital parameters (ex vivo uterine environment group) before being killed at 100-day equivalent gestational age. Umbilical artery blood samples were regularly collected to assess blood gas data, differential counts, biochemical parameters, inflammatory markers, and microbial load to exclude infection. Ultrasound was conducted at 48 hours after intraamniotic lipopolysaccharides (before surgery) to confirm fetal viability and at the conclusion of the experiments (before euthanasia) to evaluate cardiac function. Brain injury was evaluated by gross anatomic and histopathologic investigations. Eight singleton pregnant control animals were similarly exposed to intraamniotic lipopolysaccharides at 93-day gestation and were killed at 100-day gestation to allow comparative postmortem analyses (control group). Biobanked samples from age-matched saline-treated animals served as an additional comparison group. Successful instillation of lipopolysaccharides into the amniotic fluid exposure was confirmed by amniotic fluid analysis at the time of administration and by analyzing cytokine levels in fetal plasma and amniotic fluid. Data were tested for mean differences using analysis of variance. RESULTS: Six of 8 lipopolysaccharide control group (75%) and 8 of 10 ex vivo uterine environment group fetuses (80%) successfully completed their protocols. Six of 8 ex vivo uterine environment group fetuses required dexamethasone phosphate treatment to manage profound refractory hypotension. Weight and crown-rump length were reduced in ex vivo uterine environment group fetuses at euthanasia than those in lipopolysaccharide control group fetuses (P<.05). There were no biologically significant differences in cardiac ultrasound measurement, differential leukocyte counts (P>.05), plasma tumor necrosis factor α, monocyte chemoattractant protein-1 concentrations (P>.05), or liver function tests between groups. Daily blood cultures were negative for aerobic and anaerobic growth in all ex vivo uterine environment group animals. No cases of intraventricular hemorrhage were observed. White matter injury was identified in 3 of 6 lipopolysaccharide control group fetuses and 3 of 8 vivo uterine environment group fetuses. CONCLUSION: We report the use of an artificial placenta-based system to support extremely preterm lambs compromised by exposure to intrauterine inflammation. Our data highlight key challenges (refractory hypotension, growth restriction, and white matter injury) to be overcome in the development and use of artificial placenta technology for extremely preterm infants. As such challenges seem largely absent from studies based on healthy pregnancies, additional experiments of this nature using clinically relevant model systems are essential for further development of this technology and its eventual clinical application.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Usuda H, Watanabe S, Saito M, et al. Successful use of an artificial placenta-based life support system to treat extremely preterm ovine fetuses compromised by intrauterine inflammation. Am J Obstet Gynecol. 2020. PMID: 32380175. doi:10.1016/j.ajog.2020.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。